RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cardiol Therapeutics Stock

Cardiol Therapeutics Debt 2025

Cardiol Therapeutics Debt

-34.76 CAD

Ticker

CRDL.TO

ISIN

CA14161Y2006

WKN

A2PA9E

In 2025, Cardiol Therapeutics's total debt was -34.76 CAD, a -41.49% change from the -59.4 CAD total debt recorded in the previous year.

Cardiol Therapeutics Aktienanalyse

What does Cardiol Therapeutics do?

Cardiol Therapeutics Inc is an international biopharmaceutical company specializing in the development of innovative therapies for the treatment of heart diseases. The company was founded in 2006 in Canada and has since built a broad portfolio of products and technologies to improve the treatment of heart diseases. The company's business model is based on research and development of innovative therapies that aim to provide patients with more effective treatments for heart diseases. They collaborate closely with renowned research institutions and clinics worldwide to develop a wide range of innovative treatment options. The company has also specialized in the study of cannabinoids for the treatment of heart diseases, focusing on the development of medications tailored to the needs of patients with heart diseases. They have developed CardiolRx, a patented technology based on cannabinoids, which has shown promising results in clinical studies for the treatment of severe heart diseases such as heart failure and myocarditis. Overall, Cardiol Therapeutics Inc is a biopharmaceutical company dedicated to developing therapies for the treatment of heart diseases, with a focus on collaboration, innovative products, and the potential to significantly improve patient care. Cardiol Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Cardiol Therapeutics's Debt Structure

Cardiol Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Cardiol Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Cardiol Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Cardiol Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Cardiol Therapeutics stock

What is the debt of Cardiol Therapeutics this year?

Cardiol Therapeutics has a debt level of -34.76 CAD this year.

What was the debt of Cardiol Therapeutics compared to the previous year?

The debt of Cardiol Therapeutics has increased by -41.49% compared to the previous year dropped.

What are the consequences of high debt for investors in Cardiol Therapeutics?

High debt can pose a risk for investors of Cardiol Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Cardiol Therapeutics?

Low debt means that Cardiol Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Cardiol Therapeutics affect the company?

An increase in debt of Cardiol Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Cardiol Therapeutics affect the company?

A reduction in debt of Cardiol Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Cardiol Therapeutics?

Some factors that can influence the debt of Cardiol Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Cardiol Therapeutics so important for investors?

The debts of Cardiol Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Cardiol Therapeutics take to change the debt?

To change the debt, Cardiol Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Cardiol Therapeutics pay?

Over the past 12 months, Cardiol Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cardiol Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Cardiol Therapeutics?

The current dividend yield of Cardiol Therapeutics is .

When does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cardiol Therapeutics?

Cardiol Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cardiol Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cardiol Therapeutics located?

Cardiol Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cardiol Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cardiol Therapeutics from 1/23/2025 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 1/23/2025.

When did Cardiol Therapeutics pay the last dividend?

The last dividend was paid out on 1/23/2025.

What was the dividend of Cardiol Therapeutics in the year 2024?

In the year 2024, Cardiol Therapeutics distributed 0 CAD as dividends.

In which currency does Cardiol Therapeutics pay out the dividend?

The dividends of Cardiol Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cardiol Therapeutics

Our stock analysis for Cardiol Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cardiol Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.